These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32479668)

  • 1. Clinical data for intravenous iron - debunking the hype around hypersensitivity.
    Achebe M; DeLoughery TG
    Transfusion; 2020 Jun; 60(6):1154-1159. PubMed ID: 32479668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
    Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
    Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 4. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.
    Blumenstein I; Shanbhag S; Langguth P; Kalra PA; Zoller H; Lim W
    Expert Opin Drug Saf; 2021 Jul; 20(7):757-769. PubMed ID: 33993818
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
    Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
    J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
    Auerbach M; Achebe MM; Thomsen LL; Derman RJ
    Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
    Fukumoto S; Murata T; Osuga Y; Pollock RF
    Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
    Adkinson NF; Strauss WE; Macdougall IC; Bernard KE; Auerbach M; Kaper RF; Chertow GM; Krop JS
    Am J Hematol; 2018 May; 93(5):683-690. PubMed ID: 29417614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.
    Ehlken B; Nathell L; Gohlke A; Bocuk D; Toussi M; Wohlfeil S
    Drug Saf; 2019 Mar; 42(3):463-471. PubMed ID: 30535629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017.
    Durup D; Schaffalitzky de Muckadell P; Strom CC
    Expert Rev Hematol; 2020 May; 13(5):557-564. PubMed ID: 32129113
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.
    Bager P; Hvas CL; Dahlerup JF
    Br J Clin Pharmacol; 2017 May; 83(5):1118-1125. PubMed ID: 27859495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions.
    Adkinson NF; Strauss WE; Bernard K; Kaper RF; Macdougall IC; Krop JS
    J Blood Med; 2017; 8():155-163. PubMed ID: 29033620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
    Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures.
    Nathell L; Gohlke A; Wohlfeil S
    Drug Saf; 2020 Jan; 43(1):35-43. PubMed ID: 31583644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
    Yun L; YuMei Z; Bn V; Tang Q; Feng C
    Cureus; 2023 Nov; 15(11):e48717. PubMed ID: 38094535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.